Skip to main content
Premium Trial:

Request an Annual Quote

Precision for Medicine Acquires ApoCell

NEW YORK (GenomeWeb) – Precision for Medicine said today that it has acquired Houston-based ApoCell, which specializes in the identification and analysis of biomarkers in both tissue and liquid biopsy.

Specific terms of the deal were not disclosed.

The acquisition adds ApoCell's ApoStream liquid biopsy technology and its expertise in tissue genomic profiling to Precision's existing suite of specialty laboratory and biomarker informatics services, which include cell-based assays and various immune monitoring technologies.

ApoCell co-developed the ApoStream liquid biopsy tech in conjunction with the National Cancer Institute. The platform allows for the detection, isolation, and capture of circulating tumor cells and other rare cells without the need for labels or antibodies. Applications of the technology so far include studies in prostate, lung, breast, colon, pancreatic, liver, sarcoma, and renal cancers.

For tissue analysis, ApoCell offers an integrated platform for parallel generation of both phenotypic and genomic information from the same tissue biopsy sample, including high complexity, multiplex immunofluorescence detection.

The Scan

Omicron's Emergence

The World Health Organization has called Omicron a SARS-CoV-2 "variant of concern," the Los Angeles Times writes.

Not as Much

Merck's pill to treat COVID-19 reduces the risk of hospitalization and death among COVID-19 patients by less than previously reported, the New York Times says.

Bats That Hang Together

Discover magazine writes that researchers have found a social microbiome among vampire bats.

PLOS Papers on CEWAS, Simian Varicella Virus Transcriptome, Dermatomyositis Markers

In PLOS this week: multi-omic approach to home in on genetic risk variants, transcriptomic analysis of the simian varicella virus, and more.